MA55565A - Agents de dégradation de stat et leurs utilisations - Google Patents

Agents de dégradation de stat et leurs utilisations

Info

Publication number
MA55565A
MA55565A MA055565A MA55565A MA55565A MA 55565 A MA55565 A MA 55565A MA 055565 A MA055565 A MA 055565A MA 55565 A MA55565 A MA 55565A MA 55565 A MA55565 A MA 55565A
Authority
MA
Morocco
Prior art keywords
stat
degrading agents
degrading
agents
stat degrading
Prior art date
Application number
MA055565A
Other languages
English (en)
Inventor
Nan Ji
Nello Mainolfi
Bin Yang
Yi Zhang
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of MA55565A publication Critical patent/MA55565A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
MA055565A 2019-04-05 2020-04-06 Agents de dégradation de stat et leurs utilisations MA55565A (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962830095P 2019-04-05 2019-04-05
US201962833331P 2019-04-12 2019-04-12
US201962855259P 2019-05-31 2019-05-31
US201962860512P 2019-06-12 2019-06-12
US201962875362P 2019-07-17 2019-07-17
US201962877051P 2019-07-22 2019-07-22
US201962887872P 2019-08-16 2019-08-16
US201962926127P 2019-10-25 2019-10-25
US201962932957P 2019-11-08 2019-11-08
US201962944810P 2019-12-06 2019-12-06
US201962947310P 2019-12-12 2019-12-12
US201962949053P 2019-12-17 2019-12-17
US202062967921P 2020-01-30 2020-01-30

Publications (1)

Publication Number Publication Date
MA55565A true MA55565A (fr) 2022-02-09

Family

ID=72667015

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055565A MA55565A (fr) 2019-04-05 2020-04-06 Agents de dégradation de stat et leurs utilisations

Country Status (15)

Country Link
US (3) US11485750B1 (fr)
EP (1) EP3946360A4 (fr)
JP (1) JP2022527114A (fr)
KR (1) KR20220006139A (fr)
CN (1) CN113939300A (fr)
AU (1) AU2020253633A1 (fr)
BR (1) BR112021019748A2 (fr)
CA (1) CA3135802A1 (fr)
CO (1) CO2021013339A2 (fr)
IL (1) IL286969A (fr)
MA (1) MA55565A (fr)
MX (1) MX2021012216A (fr)
SG (1) SG11202110829YA (fr)
TW (1) TW202106676A (fr)
WO (1) WO2020206424A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210269803A1 (en) * 2018-06-15 2021-09-02 City Of Hope Oligonucleotide-based proteolysis targeting chimera
TW202106676A (zh) 2019-04-05 2021-02-16 美商凱麥拉醫療公司 Stat降解劑及其用途
JP7424115B2 (ja) 2019-06-26 2024-01-30 住友化学株式会社 エステル化合物の製造方法
AU2021238333A1 (en) * 2020-03-17 2022-09-29 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US20230159573A1 (en) * 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
US11988649B2 (en) * 2020-10-06 2024-05-21 Board Of Regents, The University Of Texas System On-line suppressor
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
WO2023059792A1 (fr) * 2021-10-06 2023-04-13 C4 Thrapeutics, Inc. Composés de dégradation de la protéine 3 non structurale de coronavirus
CA3236262A1 (fr) * 2021-10-25 2023-05-04 Isaac Marx Agents de degradation de tyk2 et leurs utilisations
CA3239730A1 (fr) * 2021-12-11 2023-06-15 Christopher De Savi Agents de degradation de stat3 et leurs utilisations
WO2023192960A1 (fr) * 2022-03-31 2023-10-05 Recludix Pharma, Inc. Modulateurs de stat et leurs utilisations
WO2023250058A1 (fr) * 2022-06-22 2023-12-28 Kymera Therapeutics, Inc. Agents de dégradation de stat et leurs utilisations
WO2024064080A1 (fr) * 2022-09-19 2024-03-28 Kymera Therapeutics, Inc. Agents de dégradation de stat6 et leurs utilisations

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5360811A (en) 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
JP3545461B2 (ja) 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
AP1905A (en) 1999-12-10 2008-10-20 Pfizer Prod Inc Pyrrolo[2,3-d] Pyrimidine Compounds.
DE10002509A1 (de) 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
US6465507B2 (en) 2000-02-28 2002-10-15 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
EP1322750A4 (fr) 2000-09-08 2004-09-29 California Inst Of Techn Medicament chimere de ciblage de proteolyse
WO2002078617A2 (fr) * 2001-03-28 2002-10-10 University Of South Florida Materiaux et methodes de traitement du cancer et d'identification de composes anti-cancereux
EP1389617B1 (fr) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
BRPI0409063A (pt) 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pró medicamentos de inibidor de pi-3 cinase
EP1644363B1 (fr) 2003-05-30 2012-02-22 Gemin X Pharmaceuticals Canada Inc. Composes triheterocycliques, compositions et procedes de traitement du cancer
WO2005007623A2 (fr) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition de l'expression d'une syk kinase
CN102603565A (zh) 2003-12-11 2012-07-25 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
JP4398263B2 (ja) 2004-01-13 2010-01-13 富士通株式会社 経路設計方法
US7436318B2 (en) 2004-04-19 2008-10-14 Atg Designworks, Llc Self contained device for displaying electronic information
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20060005147A1 (en) 2004-06-30 2006-01-05 Hammack Jason L Methods and systems for controlling the display of maps aboard an aircraft
US20070010428A1 (en) 2004-09-03 2007-01-11 Mcmurray John S Inhibitors of signal transduction and activator of transcription 3
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
CA2599393A1 (fr) 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Petites molecules inhibitrices du stat3 et leurs utilisations
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
PT1888550E (pt) 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US20080139456A1 (en) 2005-09-30 2008-06-12 Burke Terrence R Macrocyclic Sh2 Domain Binding Inhibitors
AU2006302179C1 (en) 2005-10-07 2013-06-20 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ZA200803226B (en) 2005-10-13 2009-11-25 Orchid Res Lab Ltd Heterocyclic Compounds as Pstat3/IL-6 Inhibitors
RU2589878C2 (ru) 2005-11-01 2016-07-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
LT2474545T (lt) 2005-12-13 2017-02-27 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
CA2634743C (fr) 2005-12-23 2014-07-29 Zealand Pharma A/S Composes modifies mimetiques de la lysine
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
NZ572812A (en) 2006-04-26 2010-09-30 Hoffmann La Roche THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
WO2007136858A2 (fr) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Petites molécules inhibitrices de stat3 ayant une activité antitumorale
EP2201840B1 (fr) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de Bruton
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
WO2008067270A1 (fr) 2006-11-27 2008-06-05 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibiteurs de liaison au domaine grb2 sh2 macrocyclique
ES2557930T3 (es) 2007-03-12 2016-01-29 Ym Biosciences Australia Pty Ltd Compuestos de fenilaminopirimidina y usos de los mismos
WO2008118802A1 (fr) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Composés thérapeutiques
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008156644A2 (fr) 2007-06-14 2008-12-24 Frank David A Modulateurs de stat
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
WO2009032338A1 (fr) 2007-09-09 2009-03-12 University Of Florida Research Foundation Agents thérapeutiques à base d'apratoxine : mécanisme et procédés de traitement
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
CA2932121A1 (fr) 2007-11-30 2009-06-11 Newlink Genetics Corporation Inhibiteurs de l'ido
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
RS55263B1 (sr) 2008-03-11 2017-02-28 Incyte Holdings Corp Derivati azetidina i ciklobutana kao jak inhibitori
WO2009132238A2 (fr) 2008-04-24 2009-10-29 Newlink Genetics Inhibiteurs de l’ido
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8143412B2 (en) 2008-07-08 2012-03-27 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2373658A4 (fr) 2008-12-08 2012-05-23 Univ Michigan Office Of Technology Transfer Inhibiteurs de stat3 et méthodes thérapeutiques les utilisant
EP4169951A1 (fr) 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
US8841257B2 (en) 2009-04-10 2014-09-23 Board Of Regents, The University Of Texas System Inhibitors of STAT3 and uses thereof
AU2010236389A1 (en) 2009-04-15 2011-11-24 Nationwide Children's Hospital, Inc. Curcumin analogs as dual JAK2/STAT3 inhibitors and methods of making and using the same
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
WO2011056652A1 (fr) 2009-10-28 2011-05-12 Newlink Genetics Dérivés imidazole comme inhibiteurs de l'ido
CA2781706A1 (fr) 2009-11-24 2011-06-03 The Ohio State University Inhibiteurs de facteur de transcription et compositions, formulations et procedes apparentes
CA2780692C (fr) 2009-12-10 2018-09-11 F. Hoffmann-La Roche Ag Anticorps se liant de facon preferentielle au domaine extracellulaire 4 de csf1r humain et leur utilisation
US8445517B2 (en) 2009-12-11 2013-05-21 Dana-Farber Cancer Institute Stat modulators
EA022458B1 (ru) 2009-12-28 2016-01-29 Дженерал Инкорпорейтед Ассошиэйшн Фарма Вэлли Проджект Саппортинг Организейшн 1,3,4-оксадиазол-2-карбоксамидное соединение
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
US8206715B2 (en) 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
CA2813571A1 (fr) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Analogues d'acide 2-(9h-purin-9-yl)acetique substitues en tant qu'inhibiteurs de stat3
AU2011272860A1 (en) 2010-06-30 2013-02-07 Brandeis University Small-molecule-targeted protein degradation
CA2807292C (fr) 2010-08-02 2019-10-22 University Of Central Florida Research Foundation, Inc. Analogues de l'acide 2-hydroxy-4-(2-(phenylsulfonamido)acetamido) benzoique substitue utilisables en tant qu'inhibiteurs des proteines stat
EP2614082B1 (fr) 2010-09-09 2018-10-03 Pfizer Inc Molécules de liaison 4-1bb
WO2012078559A2 (fr) 2010-12-07 2012-06-14 Yale University Marquage hydrophobe de petites molécules de protéines de fusion et dégradation induite de celles-ci
ES2700966T3 (es) 2010-12-09 2019-02-20 Univ Pennsylvania Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer
WO2012078982A2 (fr) 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibe la phosphorylation de stat3 constitutive et induite par l'interleukine 6 dans des cellules de carcinome hépatocellulaire humain
WO2012097351A1 (fr) 2011-01-14 2012-07-19 The Ohio State University Research Foundation Matériels et procédés d'inhibition de cellules cancéreuses de myélome multiple
WO2012142615A2 (fr) 2011-04-14 2012-10-18 Board Of Regents, The University Of Texas System Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs
NO2694640T3 (fr) 2011-04-15 2018-03-17
WO2012145493A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
SG11201402603WA (en) 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013087699A1 (fr) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Anticorps contre le csf-1r humain et leurs utilisations
EP2802608A4 (fr) 2012-01-12 2015-08-05 Univ Yale Composés et procédés pour la dégradation améliorée de protéines cibles et d'autres polypeptides par une e3 ubiquitine ligase
WO2013106646A2 (fr) 2012-01-12 2013-07-18 Yale University Composés et procédés pour l'inhibition de l'ubiquitine ligase vcb e3
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013169264A1 (fr) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Méthodes destinées à traiter des affections avec des anticorps qui se lient au récepteur du facteur 1 de stimulation des colonies (csf1r)
CN105120854B (zh) 2012-05-25 2019-04-09 多伦多大学管理委员会 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
WO2013187965A1 (fr) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Dérivés de pyrazole en tant qu'inhibiteurs de stat3
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2884971A4 (fr) 2012-08-16 2016-01-06 Ohio State Innovation Foundation Inhibiteurs de stat3 et leur utilisation anticancéreuse
TWI713436B (zh) 2012-08-31 2020-12-21 美商戊瑞治療有限公司 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
RU2015112192A (ru) 2012-09-19 2016-11-10 Ф. Хоффманн-Ля Рош Аг 2-оксо-2,3,4,5-тетрагидро-1н-бензо[b]диазепины и их применение при лечении рака
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9822135B2 (en) 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
WO2014153495A2 (fr) 2013-03-22 2014-09-25 University Of Hawaii Nouveaux inhibiteurs de stats3
WO2014205416A1 (fr) 2013-06-20 2014-12-24 University Of Hawaii Nouveaux inhibiteurs de stat3 sesquiterpénoïdes
KR20160085878A (ko) 2013-11-18 2016-07-18 에프. 호프만-라 로슈 아게 테트라하이드로-벤조다이아제핀온
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
KR20240038809A (ko) 2014-04-14 2024-03-25 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP3160486B1 (fr) 2014-06-27 2020-11-18 Celgene Corporation Compositions et procédés pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
KR101697062B1 (ko) 2014-08-26 2017-01-18 한국생명공학연구원 물에 대한 용해도가 개선된 신규 제라닐 프라보노이드 유도체, 이의 제조 방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
KR20160066490A (ko) 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
EP3256470B1 (fr) 2014-12-23 2023-07-26 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10618914B2 (en) 2015-01-15 2020-04-14 University of Pittsburgh—of the Commonwealth System of Higher Education 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20200052995A (ko) 2015-01-20 2020-05-15 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
EP3750530A1 (fr) 2015-02-05 2020-12-16 TyrNovo Ltd. Combinaisons de doubles modulateurs d'irs/stat3 et d'agents anticancéreux pour le traitement du cancer
EP3270917A4 (fr) 2015-03-18 2018-08-08 Arvinas, Inc. Composés et procédés de dégradation accrue de protéines ciblées
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016270442C1 (en) 2015-06-04 2022-06-02 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016197114A1 (fr) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs et procédés d'utilisation associés
SE539204C2 (en) 2015-06-05 2017-05-09 Glactone Pharma Dev Ab Ether analogues of galiellalactone
CN105085620B (zh) 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
WO2017007612A1 (fr) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
WO2017011371A1 (fr) 2015-07-10 2017-01-19 Arvinas, Inc Modulateurs de protéolyse à base de mdm2 et méthodes d'utilisation associées
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
EP3337476A4 (fr) 2015-08-19 2019-09-04 Arvinas, Inc. Composés et procédés pour la dégradation ciblée de protéines contenant un bromodomaine
ES2911888T3 (es) 2015-09-18 2022-05-23 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
WO2017117473A1 (fr) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Molécules bifonctionnelles de dégradation d'her3 et procédés d'utilisation
WO2017117474A1 (fr) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Composés bifonctionnels destinés à la dégradation d'her3 et procédés d'utilisation
WO2017161119A1 (fr) 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Petites molécules dirigées contre le céréblon pour améliorer la fonction des lymphocytes t effecteurs
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
RU2021102253A (ru) 2016-04-06 2021-03-03 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
CA3020281A1 (fr) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Intermediaires monofonctionnels pour la degradation d'une proteine cible dependante du ligand
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
WO2017201069A1 (fr) 2016-05-18 2017-11-23 Biotheryx, Inc. Dérivés d'oxoindoline utilisés comme modulateurs de la fonction protéique
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3042731A1 (fr) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases associees au recepteur de l'interleukine -1 et leurs utilisations
SE540295C2 (en) 2016-12-05 2018-05-29 Glactone Pharma Dev Ab Sulfonamide analogues of galiellalactone
EP3570836A4 (fr) 2017-01-23 2020-08-19 The University of Hawaii Inhibiteurs de stat3 dérivés de 2-arylsulfonamido-n-arylacétamide
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
EP3641762A4 (fr) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
WO2019043214A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Glutarimide
IL273432B (en) * 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
WO2019060693A1 (fr) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. Ligands crbn et utilisations de ces derniers
EP3700901A1 (fr) 2017-10-24 2020-09-02 Genentech, Inc. Composés (4-hydroxypyrrolidin-2-yl)-hétérocycliques et leurs procédés d'utilisation
WO2019084030A1 (fr) 2017-10-24 2019-05-02 Genentech, Inc. Composés de (4-hydroxypyrrolidin-2-yl)-hydroxamate et leurs procédés d'utilisation
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
WO2019099926A1 (fr) 2017-11-17 2019-05-23 Arvinas, Inc. Composés et procédés pour la dégradation ciblée de polypeptides de kinase 4 associés au récepteur de l'interleukine 1
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11802132B2 (en) 2018-02-23 2023-10-31 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
EP3578561A1 (fr) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spirocomposés
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3817822A4 (fr) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. Agents de dégradation de protéines et leurs utilisations
WO2020010210A1 (fr) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Agents de dégradation de mertk et leurs utilisations
JP2022516401A (ja) 2018-11-30 2022-02-28 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
WO2020205467A1 (fr) * 2019-03-29 2020-10-08 The Regents Of The University Of Michigan Agents de dégradation de protéines stat3
TW202106676A (zh) 2019-04-05 2021-02-16 美商凱麥拉醫療公司 Stat降解劑及其用途
JP2022538192A (ja) 2019-06-28 2022-08-31 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびその使用
WO2020264490A1 (fr) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
WO2021011634A1 (fr) 2019-07-15 2021-01-21 Kymera Therapeutics, Inc. Agents de dégradation de protéines et leurs utilisations
US20220281831A1 (en) 2019-07-15 2022-09-08 Kymera Therapeutics, Inc. Fused-glutarimide crbn ligands and uses thereof
WO2021011871A1 (fr) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Agents de dégradation de mertk et leurs utilisations
WO2021011868A1 (fr) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
EP4072591A4 (fr) 2019-12-10 2024-06-05 Kymera Therapeutics, Inc. Agents de dégradation d'irak et leurs utilisations
TW202136251A (zh) 2019-12-17 2021-10-01 美商凱麥拉醫療公司 Irak降解劑及其用途
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US20230219945A1 (en) 2019-12-17 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4100004A4 (fr) 2020-02-03 2024-02-28 Kymera Therapeutics, Inc. Agents de dégradation de kinases irak et leurs utilisations

Also Published As

Publication number Publication date
US11485750B1 (en) 2022-11-01
US20230084113A1 (en) 2023-03-16
CO2021013339A2 (es) 2022-01-17
BR112021019748A2 (pt) 2021-12-07
EP3946360A1 (fr) 2022-02-09
SG11202110829YA (en) 2021-10-28
IL286969A (en) 2021-12-01
US20230120381A1 (en) 2023-04-20
MX2021012216A (es) 2022-01-24
US11746120B2 (en) 2023-09-05
AU2020253633A1 (en) 2021-11-04
KR20220006139A (ko) 2022-01-14
TW202106676A (zh) 2021-02-16
EP3946360A4 (fr) 2023-05-10
WO2020206424A1 (fr) 2020-10-08
JP2022527114A (ja) 2022-05-30
CN113939300A (zh) 2022-01-14
CA3135802A1 (fr) 2020-10-08

Similar Documents

Publication Publication Date Title
MA55565A (fr) Agents de dégradation de stat et leurs utilisations
MA55627A (fr) Agonistes de glp-1r et leurs utilisations
MA52483A (fr) Dérivés de gip et leurs utilisations
MA56462A (fr) Inhibiteurs de hpk1 et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
MA49971A (fr) Vésicules extracellulaires modifiées et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA50502A (fr) Adénovirus et utilisations associées
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA43529A (fr) Modulateurs de transport nucléaire et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA53660A (fr) Analogues de stérol et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA55083A (fr) Polyribonucléotides et leurs utilisations cosmétiques
MA54319A (fr) Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
MA44489A (fr) Pyrimidines et variants de celles-ci, et leurs utilisations
MA51840A (fr) Modulateurs de somatostatine et leurs utilisations